Kehoe Law Firm, P.C. is investigating securities claims on behalf of investors of BioAge Labs, Inc. (“BioAge” or the “Company”) (NASDAQ:BIOA) who purchased BioAge stock pursuant or traceable to the registration statement for its initial public offering (“IPO”) which occurred on or about September 26, 2024.
BioAge investors who obtained their securities pursuant or traceable to the Company’s IPO are encouraged to send us a message or complete Kehoe Law Firm’s Stockholder Information Request form to discuss their rights with an attorney.
Class Action Lawsuit Filed Against BioAge
A class action lawsuit has been filed in federal court against BioAge alleging violations of federal securities laws on behalf of investors who acquired BioAge stock in connection with the Company’s September 2024 IPO.
On or about September 26, 2024, BioAge, “a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases,” conducted its IPO, selling 12,650,000 shares of common stock at $18.00 per share.
On December 6, 2024, BioAge announced the discontinuation of its STRIDES Phase 2 study of azelaprag. The company stated, among other things, that the emerging safety profile of the drug was inconsistent with its goal of a best-in-class oral obesity therapy.
Following this news, BioAge’s stock price plummeted $15.44 per share (76.85%), closing at $4.65 per share on December 9, 2024.
BioAge Shareholders: Learn More About the Securities Class Action and Your Legal Options
Investors who acquired their BioAge stock pursuant or traceable to the Company’s IPO can also contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected], to discuss the securities class action and receive a free, no-obligation legal evaluation.
Investors who purchased BioAge stock pursuant to the Company’s IPO have until March 10, 2025 to petition the Court for appointment as lead plaintiff. The Court typically appoints the investor with the largest financial interest who also meets the adequacy and typicality requirements. Investors who wish to discuss their rights or the lead plaintiff process are encouraged to contact our firm.
About Kehoe Law Firm, P.C.
Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action firm dedicated to protecting investors and consumers from fraud and misconduct. Our attorneys have served as Lead or Co-Lead Counsel in major securities cases, recovering over $10 billion for institutional and individual investors.
Our firm litigates securities fraud, fiduciary breaches, unfair mergers and acquisitions, and antitrust violations, while also representing whistleblowers and advocating for victims of data breaches, consumer fraud, vehicle and product defects, employment law violations, retirement plan mismanagement, and other corporate and business misconduct. With a results-driven approach, we pursue justice and substantial recoveries for those we represent.
Kehoe Law Firm’s class action legal services are provided on a contingency-fee basis, meaning clients are not responsible for any fees or litigation expenses.
SEND US A MESSAGE
Contact Us
ADDRESS
Kehoe Law Firm, P.C.
2001 Market Street
Suite 2500
Philadelphia, PA 19103